JPM 2022: Pfizer re-ups gene editing interest with $300M Beam pact, $1.35B in biobucks

Retrieved on: 2022-01-10 17:10:47

Tags for this article:

Click the tags to see associated articles and topics

JPM 2022: Pfizer re-ups gene editing interest with $300M Beam pact, $1.35B in biobucks. View article details on hiswai:

Excerpt

Pfizer is taking a bigger bite out of the gene editing apple with $300 million upfront in a research collaboration with Beam Therapeutics focused ...

Article found on: www.fiercebiotech.com